“Ante la duda, usad Haloperidol”. ¿O no?

  • Ignacio Jáuregui-Lobera Instituto de Ciencias de la Conducta y Universidad Pablo de Olavide de Sevilla
  • Jesus M. Culebras De la Real Academia de Medicina de Valladolid y del IBIOMED, Universidad de León Académico Asociado al Instituto de España AcProfesor Titular de Cirugía Director, Journal of Negative & No Positive Results Director Emérito de NUTRICION HOSPITALARIA
Palabras clave: -

Resumen

-

Descargas

La descarga de datos todavía no está disponible.

Citas

Oransky I. Paul Janssen (Obituary). The Lancet 2004;363:251.

Medrano J. Boticarium. Rev Asoc EspNeuropsiq2014;34:175-194.

Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, et al. Haloperidol and Ziprasidone for treatmentof delirium in critical illness. NEnglJMed 2018;379;2506-16.

López-Muñoz F, Alamo C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res Bull 2009; 79:130-41.

Latronico N. Haloperidol and delirium in the ICU: thefinger pointing to the moon. Intensive Care Med 2018;44:1346-48.

Markowitz JD, NarasimhanM. Delirium and antipsychotics:A systematic review of epidemiology and somatic treatment options. Psychiatry (Edgemont) 2008;5:29-36.

European Delirium Association y American Delirium Society. The DSM- 5 criteria, level of arousal and delirium diagnosis: inclusiveness is safer. BMC Medicine 2014;12:141.

Shen Y. · Peng K. · Zhang J. · Meng X. · Ji F. Effects of Haloperidol on Delirium in Adult Patients: A Systematic Review and Meta-Analysis. Med Princ Pract 2018;27:250–259 https://doi.org/10.1159/000488243

Bleck TP. Dopamine antagonists in ICU delirium. NEnglJMed 2018;379;2569-70.

Publicado
2019-04-22